Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis

Circulation

Volumn 93, Issue 1, 1996, Pages 153-160

  Biemond, Bart J ^a,c   Friederich, Philip W ^a   Levi, Marcel ^a   Vlasuk, George P ^b   Büller, Harry R ^a   Ten Cate, Jan W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Dendreon   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

anticoagulants; fibrinolysis; thrombosis

Indexed keywords

CVS 995; HIRULOG; LEPIRUDIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; FIBRIN FORMATION; FIBRINOLYTIC THERAPY; INTRAARTERIAL DRUG ADMINISTRATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RABBIT; VEIN THROMBOSIS;

EID: 0030022915     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.1.153     Document Type: Article

References (35)

1. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
2. Marder VJ, Soulen RL, Atichartakarn V, Budzynski AZ, Parulekar S, Kim JR, Edward N, Zahari J, Algazy KM. Quantitative venografic assessment of deep venous thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med. 1977;89: 1018-1029.
3. Bratt G, Tornebohm E, Gragvist S, Aberg, Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost. 1985;54:813-817.
4. Brandjes DPM, Heyboer H, Büller HR, de Rijk M, Jagt H, ten Gate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med. 1992;327:1485-1489.
5. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L, Geert M. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med. 1986;315:1109-1114.
6. Hull RD, Raskob GE, Rosenbloom D, Lemaire J, Pineo GF, Baylis B, Ginsberg JS, Panju AA, Brill-Edwards P, Brant R. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med. 1992;152:1589-1595.
7. GISSI-2. A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990;1:65-71.
8. Agnelli G, Renga C, Weitz JI, Nenci GG, Hirsh J. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. Blood. 1992;80:960-965.
9. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
10. van den Bos AA, Deckers JW, Heyndrickx GR, Laarman GJ, Suryapranata H, Zijlstra F, Close P, Rijnierse JJMM, Büller HR, Serruys PW. Safety and efficacy of recombinant hirudin (CGP 39393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation. 1993;88:2058-2066.
11. Heras MH, Chesebro JH, Penny WJ, Kent RB, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation. 1989;79:657-665.
12. Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science. 1990;248:593-596.
13. Neeper MP, Waxman L, Smith DE, Schulman CA, Sardana M, Ellis RW, Schaffer LW, Siegl PKS, Vlasuk GP. Characterisation of recombinant tick anticoagulant peptide: a highly selective inhibitor of blood coagulation factor Xa. J Biol Chem. 1990;265:17746-17752.
14. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterisation of Hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry. 1990;29: 7095-7101.
15. Skrzypczak-Jankun E, Carperos VE, Ravichandran KG, Tulinsky A. Structure of the hirugen and Hirulog-1 complexes of α-thrombin. J Mol Biol. 1991;221:1379-1393.
16. Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, Hanson D, Mant T, Wagner J, Maraganore J. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost. 1993;69:157-163.
17. Cannon CP, Maraganore JM, Loscalzo J, McAlister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E, Ganz P. Anticoagulant effects of Hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol. 1993;71: 778-782.
18. Yao SK, McNatt J, Anderson HJ, Eidt J, Cui KX, Golino, Glas-Greenwalt P, Maraganore J, Buja LM, Willerson JT. Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion. Am J Physiol. 1992;262: 374-379.
19. Klement P, Borm A, Hirsh J, Maraganore J, Wilson G, Weitz J. The effect of thrombin inhibitors on tissue plasminogen activator-induced thrombolysis in a rat model. Thromb Haemost. 1992;68: 64-68.
20. Schaffer LW, Davidson JT, Vlasuk GP, Siegl PKS. Antithrombotic efficacy of recombinant tick anticoagulant peptide: a potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation. 1991;84:1741-1748.
21. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with selective factor Xa inhibitor, tick anticoagulant peptide. Circulation. 1992;85:805-815.
22. Vlasuk GP, Ramjit D, Fujita T, Dunwiddie CT, Nutt EM, Smith DE, Shebuski RJ. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost. 1991;65:257-262.
23. Nurmohamed MT, Rosendaal FR, Büller HR, Dekker E, Hommes DW, Vanden Broucke JP, Briët E. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 1992;1:152-156.
24. Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW. Comparison of subcutaneous low-molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992;1:441-445.
25. Vlasuk GP, Vallar PL, Weinhouse MI, Bergum PW, Tran HS, Weitz JI, Tulinsky A, Krishnnan R, Rote WE, Oldeschulte GL, Pearson DA. A novel inhibitor of thrombin containing multiple recognition sequences linked by a α-keto amide transition state mimetic. Circulation. 1994;90(suppl I):I-348. Abstract.
26. Laroche Y, Storme V, DeMeutter J, Messens J, Lauwereys M. High-level secretion and very efficint isotropic labeling of tick anticoagulant peptide (TAP) expressed in the methylotrophic yeast, Piscina pastoris. Biotechnology. 1994;12:1119-1124.
27. Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G. A simple sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost. 1982;48:266-269.
28. Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost. 1984;51:392-395.
29. Van Hinsberg VWM, Sprengers ED, Kooistra T. Effect of thrombin on the production of plasminogen activators and PA inhibitor-1 by human foreskin microvascular endothelial cells. Thromb Haemost. 1987;57:148-153.
30. Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamin. J Lab Clin Med. 1987;109:97-104.
31. Francis CW, Marder VJ. Increased resistance to plasmic degradation of fibrin with highly cross-linked α-polymer chains formed at high factor XIII concentrations. Blood. 1988;71:1361-1365.
32. Van Giezen JJJ, Minkema J, Bouma BN, Jansen JWCM. Crosslinking of α2-antiplasmin to fibrin is a key factor in regulation blood clot lysis: species difference. Blood Coagul Fibrinol. In press.
33. Mosesson MW. Fibrin polymerisation and its regulatory role in haemostasis. J Lab Clin Med. 1990;116:8-17.
34. Sakata Y, Aoki N. Cross-linking of α2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest. 1980;65:290-297.
35. Witting WI, Bourdon P, Brezniak DV, Maraganore JM, Fenton JW. Thrombin-specific inhibition by and slow cleavage of Hirulog-1. Biochem J. 1992;283:737-743.